Southern Cross University invites participants to a clinical trial at Southern Cross University that will examine the effectiveness of using medical cannabis in treating anxiety disorders among adult autistics.
Autism spectrum disorder (ASD), also known as autism, is a neurological condition that causes social and communication problems, limited and repetitive behaviours and interests, and increased sensory sensitivity. Autism sufferers can be anxious because of their sensitivities.
Aspect (Autism Spectrum Australia), according to Aspect, it is likely that at least 1 in 40 Australians are on the autism spectrum — which can range from mild to profound. Autism may seem to be increasing, but it is likely due to increased awareness and improved diagnostic abilities of healthcare professionals.
Autism is managed by a number of different treatments. Some of these can lead to significant side-effects. Cannabis has become a popular alternative to conventional treatment, although more research needs to be done.
The National Centre for Naturopathic Medicine of Southern Cross University is conducting a trial at the University’s Clinical Trials Centre in Lismore, New South Wales.
The Principal Investigator is Professor Andrew Cashin of Autism and intellectual disability.
This clinical trial is designed to help us understand whether medicinal cannabis may be helpful for ASD adults. says Professor Cashin.
In the next few months, 24 people over 18 years old will be invited to participate in the study. They will get gift cards as a reward for participating. Six face-to-face meetings are scheduled during the 15-week study, which includes blood and urine testing. The Australian-funded trial will determine if a cannabis medicinal product is effective in helping ASD adults manage their anxiety.
If you are eligible for the study, the team will contact you with more information. pre-screening survey here.
A trial in Australia is exploring the potential benefits of medicinal cannabis for children with autism and their parents. This trial is a collaboration of Medigrowth and Deakin University. It involves using a CBD-based medication in order to determine if this improves social function and reduces anxiety, as well as reducing stress for parents.